Oncare, a Bengaluru-based oncology care startup, has secured ₹27 crore in Series A funding to scale its network of specialized cancer care centres and enhance its tech-enabled treatment platform. The round will fuel expansion into new cities, strengthen clinical partnerships, invest in advanced treatment technologies, and improve access to affordable, high-quality cancer care in tier-2 and tier-3 markets.
Glimpse:
Led by a consortium of healthcare-focused investors and strategic angels, the ₹27 crore Series A will enable Oncare to open additional day-care oncology centres, integrate more AI-driven treatment planning and patient monitoring tools, expand its multidisciplinary team of oncologists, and deepen collaborations with hospitals and diagnostic chains. The company aims to serve over 50,000 cancer patients annually within the next 3 years while maintaining its focus on evidence-based, patient-centric care and cost transparency.
Oncare, a fast-emerging oncology care platform headquartered in Bengaluru, has successfully closed a ₹27 crore Series A funding round, the company announced on February 26, 2026. The round was led by a group of prominent healthcare investors with strong participation from strategic angels and family offices with deep interest in oncology and digital health. The fresh capital comes at a pivotal time for Oncare, which has rapidly built a network of day-care oncology centres offering chemotherapy, immunotherapy, targeted therapy, and supportive care services with a strong emphasis on affordability and clinical excellence.
Founded in 2022 by a team of oncologists, technologists, and healthcare entrepreneurs, Oncare operates a chain of specialized day-care centres that deliver high-quality cancer treatment without requiring overnight hospital stays. The centres provide comprehensive services including medical oncology consultations, chemotherapy administration, immunotherapy infusions, targeted therapy, palliative care, pain management, and nutritional counselling—all under the supervision of experienced oncologists and trained nursing staff. The company uses a proprietary tech platform for treatment planning, patient monitoring, medication adherence tracking, and outcome analytics, ensuring personalized care pathways and transparent pricing.
The ₹27 crore infusion will be deployed across multiple growth priorities. Oncare plans to accelerate the opening of new centres in tier-2 and tier-3 cities across South and West India, where access to specialized oncology care remains limited. Funds will also support the integration of advanced technologies such as AI-assisted treatment response prediction, remote patient monitoring tools, and digital patient engagement features to improve adherence and outcomes. A portion of the capital will go toward strengthening the clinical team through hiring of additional medical oncologists, radiation oncologists, and supportive care specialists, as well as deepening partnerships with major hospitals, diagnostic labs, and insurance providers.
Speaking on the funding round, Oncare’s founders highlighted that India faces one of the world’s highest cancer burdens, with over 1.4 million new cases annually and a significant proportion diagnosed at advanced stages due to delayed access to specialized care. They emphasized that Oncare’s model of affordable day-care oncology centres combined with digital tools can dramatically improve early intervention, treatment compliance, and quality of life while reducing the financial toxicity often associated with cancer care.
The Series A round follows a successful seed round and bootstrapped growth phase in which Oncare treated thousands of patients across its existing centres in Bengaluru and Hyderabad. The company plans to use the new funding to reach over 50,000 patients annually within the next three years and establish itself as a leading organized player in India’s fragmented oncology care market.
Industry observers view the investment as a strong vote of confidence in the potential of organized, tech-enabled oncology care models in India, where the sector remains largely unorganized and dominated by standalone clinics or large hospital chains. The round also reflects growing investor interest in healthcare delivery startups that combine clinical excellence with operational scalability and patient affordability.
“Cancer care in India must be timely, affordable, and compassionate. With this funding, we are scaling a model that brings world-class oncology closer to patients who need it most without forcing them to choose between quality and cost.”
By
HB Team
